SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-133759
Filing Date
2020-05-05
Accepted
2020-05-05 16:25:15
Documents
16
Period of Report
2020-05-05
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d923428d8k.htm   iXBRL 8-K 34871
2 EX-5.1 d923428dex51.htm EX-5.1 9023
3 EX-10.1 d923428dex101.htm EX-10.1 18676
7 GRAPHIC g923428g67d67.jpg GRAPHIC 22994
8 GRAPHIC g923428g86b73.jpg GRAPHIC 8347
  Complete submission text file 0001193125-20-133759.txt   240196

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA kpti-20200505.xsd EX-101.SCH 3074
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE kpti-20200505_lab.xml EX-101.LAB 18137
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kpti-20200505_pre.xml EX-101.PRE 11410
10 EXTRACTED XBRL INSTANCE DOCUMENT d923428d8k_htm.xml XML 3348
Mailing Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459
Business Address 85 WELLS AVENUE SECOND FLOOR NEWTON MA 02459 617-658-0600
Karyopharm Therapeutics Inc. (Filer) CIK: 0001503802 (see all company filings)

IRS No.: 263931704 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36167 | Film No.: 20849280
SIC: 2834 Pharmaceutical Preparations